ATCvet code:
QM09AX90
Pharmacodynamics
This veterinary medicinal product contains tenogenic primed equine allogeneic peripheral blood-derived mesenchymal stem cells (tpMSCs). The tenogenic priming of the mesenchymal stem cells aims to promote tissue restoring and healing mechanisms in tendons, such as improving extracellular matrix production. The effects were reflected after tpMSC administration in an experimental tendon injury model in horses through improved ultrasound echogenicity and fibre scoring, higher percentages of intact and fully aligned tendon fascicles reflected by a higher collagen type I content and a lower collagen type III and smooth muscle actin presence.
In the pivotal clinical trial, efficacy of treatment compared to a placebo group was evaluated under conditions of a standard program of box rest and slowly increasing exercise regimen under veterinary guidance. A significant improvement in fibre alignment score in the tendon lesion was demonstrated which coincided with an improvement of echogenicity and size of the cross sectional area on ultrasound examinations.
Pharmacokinetics
After injection of the veterinary medicinal product, the tpMSCs do not migrate or distribute from the treated tendon to surrounding tissues or the draining lymph node.
Classification of Veterinary Medicinal Products
Veterinary medicinal product subject to prescription.
Detailed information on this veterinary medicinal product is available in the Union Product Database (https://medicines.health.europa.eu/veterinary).